Galera Therapeutics, which develops therapies to prevent side effects from cancer treatments, has completed a Novo-led series B round also featuring Novartis.
Galera Therapeutics, a US-based biotechnology company focused on cancer therapies, closed a $37m series B round led by Novo Ventures, the corporate venturing arm of healthcare company Novo, yesterday.
Novartis Venture Fund, the investment vehicle of pharmaceutical firm Novartis, also contributed to the round alongside New Enterprise Associates (NEA), Correlation Ventures and Galera Angels. Thomas Dyrberg, managing partner of Novo Ventures, will join Galera’s board of directors.
Galera is working on treatments to prevent side effects caused by chemoradiation therapy.…